Humacyte, Inc.

HUMAW·NasdaqGS

FollowCompareShare

0.0009−0.0032 (−78.05%)today

At close: Aug 25, 3:59 PM EDT · May be delayed up to 15 min · USD

1D5D1M6MYTD1Y5Y10Y20YAll

MountainLineCandles

Indicators

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close0.0041

Open0.2300

Day range0.00090.0039

52-week range0.00090.0039

Off day high−76.92%

Off 52-week high−76.92%

Volume258.66K

Avg. volume (3M)—

Market cap—

EPS (TTM)-3.16

Forward P/E—

P/E ratio (TTM)—

Dividend yield—

Beta (5Y)2.47

Shares outstanding—

Short interest—

Earnings date—

Analyst target—

Profit margin0.00%

Related companies

Compare ›

Also watched

What visitors to HUMAW's page also look at.

Company	Mkt cap	Price	Today
JSPRJasper Therapeutics, Inc.JSPRW	—	0.0002	−84.62%
HUMAHumacyte, Inc.HUMA	119.45M	0.4300	+0.23%
SABSSAB Biotherapeutics, Inc.SABSW	—	0.0072	−31.43%
KTTAPasithea Therapeutics Corp. WarrantKTTAW	—	0.0028	0.00%
DRTSAlpha Tau Medical Ltd. WarrantDRTSW	—	2.6799	−10.37%

From the 4Conservative instruments index: what each company does (its business description), its industry, size, headquarters and the markets it serves; and from a year of daily prices, which move together. Prices may be delayed up to 15 min.

Latest news

All HUMAW news ›

BioBuzz·4d agoPositive

Durham’s Humacyte to Present Phase 3 V012 Results for ATEV in Women on Hemodialysis at ASN Kidney Week 2026

Humacyte , a Durham, North Carolina-based commercial-stage biotechnology company developing universally implantable, bioengineered human tissues, announced on October 12, 2026 that interim results from its V012 Phase 3 clinical trial have…

Stock Titan·4d agoPositive

Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals

Profusa Receives ISO 13485:2016 Certificate from GMED New hospital ordering activity increased sequentially each month of the third quarter. Humacyte (HUMA) reported a 44% third-quarter increase in hospitals that have ordered Symvess, its…

Stock Titan·Oct 12Positive

Humacyte Announces Phase 3 V012 Trial Results for ATEV in Women Requiring Hemodialysis Access Accepted for a Late-Breaking Session Presentation at ASN Kidney Week 2026

Humacyte targets an FDA submission this quarter to expand the Symvess label to hemodialysis access. V012 results and two previously completed Phase 3 hemodialysis-access trials form the clinical foundation for a planned supplemental…

From articles in the 4Search news index.

In the news

2mentions in 30 days

2with it in the headline

Positivesentiment

Mentioned with

Advisory Board1American Capital Partners1American Medical Association1Barclays1Biologics License Application1Board of Directors1Depuy Synthes U.S.1Depuy Synthes U.S. Joins Peptilogics Board1

People in the coverage

Abbott1Cody Christensen1Czartoski1Geoff Martha1Gustavo Koniszczer1Humacyte1

Themes

Health22026.01Announces1Board1Clinical Medicine1Directors1FDA1Health Care1

Most coverage from

1. biobuzz.io1
2. stocktitan.net1

Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 2 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Conservative index. Terms of use.